Antibodies to watch in 2024

Antibodies to watch in 2024

The ‘Antibodies to Watch’ article series provides an annual summary of commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical development, regulatory review, and those recently granted a first approval in any country. In this installment, we discuss key details for...

Full description

Saved in:

Bibliographic Details
Main Authors:	Silvia Crescioli, Hélène Kaplon, Alicia Chenoweth, Lin Wang, Jyothsna Visweswaraiah, Janice M. Reichert
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	mAbs
Subjects:	Antibody therapeutics cancer COVID-19 European Medicines Agency Food and Drug Administration immune-mediated disorders
Online Access:	https://www.tandfonline.com/doi/10.1080/19420862.2023.2297450
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: The immune response to therapeutic antibodies
by: Michael G. Tovey, et al.
Published: (2025-02-01)

Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma
by: Charissa Wijnands, et al.
Published: (2025-01-01)

Therapeutic proteins immunogenicity: a peptide point of view
by: Feliciana Real-Fernandez, et al.
Published: (2023-10-01)

Six events that shaped antibody approvals in oncology
by: Suman Paul, et al.
Published: (2025-02-01)

Therapeutic drug monitoring and neutralizing anti-drug antibody detection to optimize TNF-alpha inhibitor treatment for uveitis
by: Howard C. Chen, et al.
Published: (2025-01-01)

Production of antibodies and antibody fragments containing non-natural amino acids in Escherichia coli
by: Jacquelyn Blake-Hedges, et al.
Published: (2024-12-01)

Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodies: a pilot study
by: Zhiliang Guo, et al.
Published: (2025-01-01)

Biparatopic antibodies: therapeutic applications and prospects
by: David L. Niquille, et al.
Published: (2024-12-01)

Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
by: Zhijuan Ai, et al.
Published: (2025-01-01)

Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates
by: Yangyang Gao, et al.
Published: (2025-01-01)

Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities
by: Nai Lee, et al.
Published: (2025-01-01)

T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics
by: Ruoxuan Sun, et al.
Published: (2024-12-01)

The kinetics of maternal and self-developed Streptococcus suis-specific antibodies
by: Sandra Vreman, et al.
Published: (2025-02-01)

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies
by: Aimee E. Mattei, et al.
Published: (2024-12-01)

Underappreciated layers of antibody-mediated immune synapse architecture and dynamics
by: Benjamin S. Goldberg, et al.
Published: (2025-01-01)

Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows
by: Caitlin Fawcett, et al.
Published: (2024-12-01)

Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based in silico approaches
by: David Hoffmann, et al.
Published: (2024-12-01)

Study of pathogenesis and immune response at experimental infection of broiler chicks with avian metapneumovirus subtype В
by: M. A. Volkova, et al.
Published: (2018-04-01)

Association of Bacterial Vaginosis and Skin Disorders in Patients with Autoimmune Antibody Positivity
by: Burcu Beksac, et al.
Published: (2021-08-01)

Clinical advances in antibody-drug conjugates for hematological malignancies
by: TANG Sijie, et al.
Published: (2024-12-01)

Therapeutic drug monitoring of atypical antipsychotic drugs
by: Grundmann Milan, et al.
Published: (2014-12-01)

Enhancing the efficacy of near-infrared photoimmunotherapy through intratumoural delivery of CD44–targeting antibody–photoabsorber conjugatesResearch in context
by: Yuichi Adachi, et al.
Published: (2025-02-01)

A New Antibody–Cytokine Construct Targeting Natural Killer Cells: An Immunotherapeutic Approach to Chronic Lymphocytic Leukemia
by: Michela Flego, et al.
Published: (2025-01-01)

Administrative act appeal within the administrative procedure: comparative legal analysis
by: O. O. Markova
Published: (2023-07-01)

Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer
by: Xiaojie Chu, et al.
Published: (2024-12-01)

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity
by: Alyssa Synan, et al.
Published: (2025-12-01)

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies
by: Wen-Ting K. Tsai, et al.
Published: (2024-12-01)

Accelerating TB regimen development: introducing FAST-TB
by: T. Devezin, et al.
Published: (2024-11-01)

Directions of harmonization of the main principles of domestic administrative and legal science with European integration requirements
by: O. Yu. Kyrychenko
Published: (2022-12-01)

Therapeutic potential of the neutralizing monoclonal antibody 45G3 against encephalomyocarditis virus
by: Yanfang Zhang, et al.
Published: (2025-01-01)

Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function
by: Jennifer L. Schwedler, et al.
Published: (2024-12-01)

Can antibodies be “vegan”? A guide through the maze of today’s antibody generation methods
by: Stefan Dübel
Published: (2024-12-01)

Coactivation of Tie2 and Wnt signaling using an antibody–R-spondin fusion potentiates therapeutic angiogenesis and vessel stabilization in hindlimb ischemia
by: Byungtae Hwang, et al.
Published: (2024-12-01)

Quantifying hope: an EU perspective of rare disease therapeutic space and market dynamics
by: Emmanuelle Cacoub, et al.
Published: (2025-02-01)

Development and evaluation of a recombinant monoclonal human antibody with virus-neutralizing activity against the F glycoprotein of respiratory syncytial virus
by: Sergey A. Klotchenko, et al.
Published: (2024-12-01)

Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors
by: Geoff Hale, et al.
Published: (2024-12-01)

Evaluation of neutralizing antibody titers against SARS-CoV-2 JN.1 omicron subvariant during pregnancy - A case series study
by: Marie Didembourg, et al.
Published: (2025-01-01)

Electrostatic properties of human germlines and biodistribution of small biologics
by: Leticia Maria De Souza Cordeiro, et al.
Published: (2024-12-01)

Antiphospholipid antibodies positivity as a potential risk factor for restenosis following arteriovenous fistula stenting in hemodialysis patients: a pilot study
by: Maxime Taghavi, et al.
Published: (2025-01-01)

Role of microvascular pericyte dysfunction in antibody-mediated rejection following kidney transplantation
by: Jie Xu, et al.
Published: (2025-12-01)